Wells Fargo has recently initiated Repligen Corp (RGEN) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 26, 2024, Deutsche Bank had raised the stock from a Hold to Buy, setting a price target of $155 for RGEN stock. Guggenheim also initiated Neutral rating. Additionally, The Benchmark Company reduced Hold rating on December 4, 2023. Wells Fargo analysts, in their report published on July 20, 2023, also initiated Overweight rating and set a price target of $185 for Repligen Corp’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Repligen Corp (RGEN) Stock Trading Recap
On Tuesday, Repligen Corp (RGEN) stock saw a decline, ending the day at $144.14 which represents a decrease of $-5.07 or -3.40% from the prior close of $149.21. The stock opened at $145 and touched a low of $142.14 during the day, reaching a high of $150.15. The volume of shares traded was 0.90 million exceeding the average volume of 0.80 million.
Sponsored
RGEN Stock Performance and Moving Averages
In recent trading, Repligen Corp (RGEN) stock price has shown some volatility, fluctuating -0.58% over the last five trades and 2.64% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -15.85%, and it has gained 9.70% in the previous three months. Currently, RGEN is trading at 1.64%, -0.57%, and -10.55% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, RGEN, a Healthcare sector stock, is trading -31.73% below its 52-week high but remains 30.50% above its 52-week low. The Average True Range (ATR) (14 days) of 6.3 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Repligen Corp’s Profitability and Valuation Ratios
Repligen Corp’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 2.51% and a profit margin of -0.32%, with a gross margin of -15.85%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Repligen Corp’s market capitalization stands at $8.07 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 77.65. Additionally, the Price-to-Sales Ratio is 13.4, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 4.06, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 6.98% of Repligen Corp (RGEN)’s shares, while financial institutions hold 103.70%.
Notable insider trades include Hunt Anthony, Director at Repligen Corp (RGEN), who sold 22191 shares on Sep 10 ’24, at $145.37 each, totaling $3.23 million. On Aug 02 ’24, KURIYEL RALF, Senior VP, R&D, sold 7148 shares for $159.35 each, amounting to $1.14 million. Additionally, on Aug 01 ’24, KURIYEL RALF sold 4465 shares at $165.67 each, generating $0.74 million.
